{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T02:22:07Z","timestamp":1790821327917,"version":"4.1.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T00:00:00Z","timestamp":1758499200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T00:00:00Z","timestamp":1758499200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"University of Bern"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Intervent Radiol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>THE primary objective of the MOTIV BTK PILOT STUDY WAs to evaluate the immediate and long-term safety and efficacy of the MOTIV\u00ae sirolimus-eluting bioresorbable scaffold (Reva Medical, San Diego, California, USA) in below-the-knee (BTK) arteries for the treatment of patients with rest pain or minor tissue loss (critical limb-threatening ischemia (CLTI)).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>This is a prospective, single-arm, multi-center trial of a novel drug-eluting bioresorbable scaffold with a new scaffold material (Tyrocore\u00ae), which includes an iodinated, polycarbonate copolymer of tyrosine analogs and has a surface coating of the same Tyrocore material and the antiproliferative drug sirolimus. Fifty-eight patients were included between August 2019 and July 2021. The primary efficacy outcome measure was primary patency at 12\u00a0months. The primary safety outcome measure was freedom from serious device-related adverse events at 30\u00a0days. Secondary outcome measures were immediate technical success, primary patency at 24 and 36\u00a0months, clinically driven target lesion revascularization rate (CD-TLR) and limb salvage at 12, 24, and 36\u00a0months. Follow-up was performed at 1, 6, 24, and 36\u00a0months, including clinical assessment and core laboratory adjudicated color duplex ultrasound.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Seventy-six MOTIV scaffolds were implanted in 60 study limbs with an average lesion length of 29.5\u00a0mm. Primary patency at 12, 24, and 36\u00a0months was 88.3%, 81.7%, and 80% (with numbers of limbs at risk being 43, 38 &amp; 30) respectively. The 30-day adverse event rate was 1.7%. Technical success was achieved in 99%. At 3\u00a0years, freedom from CD-TLR was 93% and limb salvage rate was 95%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The 36-month results of this pilot MOTIV BTK study demonstrated favorable safety and effectiveness performance in CLTI patients with BTK atherosclerotic disease.<\/jats:p>\n                    <jats:p>Level of Evidence: Level 3: non-randomized controlled cohort study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical Abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1007\/s00270-025-04202-8","type":"journal-article","created":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T19:17:50Z","timestamp":1758568670000},"page":"1576-1586","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["MOTIV Bioresorbable Scaffold in Below-The-Knee Artery Disease: European Post-Market Pilot BTK Trial: 36-Month Results"],"prefix":"10.1007","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-9419-8163","authenticated-orcid":false,"given":"Michel J.","family":"Bosiers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Rand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raman","family":"Uberoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Schroeder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nasser","family":"Malyar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dierk","family":"Scheinert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrej","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,22]]},"reference":[{"issue":"8","key":"4202_CR1","doi-asserted-by":"publisher","first-page":"e1020","DOI":"10.1016\/S2214-109X(19)30255-4","volume":"7","author":"P Song","year":"2019","unstructured":"Song P, Rudan D, Zhu Y, et al. Global, regional, and national prevalence and risk factors for peripheral artery disease in 2015: an updated systematic review and analysis. Lancet Glob Health. 2019;7(8):e1020\u201330. https:\/\/doi.org\/10.1016\/S2214-109X(19)30255-4.","journal-title":"Lancet Glob Health"},{"key":"4202_CR2","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1016\/j.jvs.2008.01.005","volume":"47","author":"M Romiti","year":"2008","unstructured":"Romiti M, Albers M, Brochado-Neto FC, et al. Meta-analysis of infrapopliteal angioplasty for chronic critical limb ischemia. J Vasc Surg. 2008;47:975\u201381. https:\/\/doi.org\/10.1016\/j.jvs.2008.01.005.","journal-title":"J Vasc Surg"},{"issue":"9","key":"4202_CR3","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/j.jvir.2009.05.031","volume":"20","author":"D Siablis","year":"2009","unstructured":"Siablis D, Karnabatidis D, Katsanos K, Diamantopoulos A, Spiliopoulos S, Kagadis GC, et al. Infrapopliteal application of sirolimus-eluting versus bare metal stents for critical limb ischemia: analysis of long-term angiographic and clinical outcome. J Vasc Interv Radiol. 2009;20(9):1141\u201350. https:\/\/doi.org\/10.1016\/j.jvir.2009.05.031.","journal-title":"J Vasc Interv Radiol"},{"issue":"1","key":"4202_CR4","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1583\/13-4486MR.1","volume":"21","author":"F Baumann","year":"2014","unstructured":"Baumann F, Fust J, Engelberger RP, H\u00fcgel U, Do DD, Willenberg T, et al. Early recoil after balloon angioplasty of tibial artery obstructions in patients with critical limb ischemia. J Endovasc Ther. 2014;21(1):44\u201351. https:\/\/doi.org\/10.1583\/13-4486MR.1.","journal-title":"J Endovasc Ther"},{"key":"4202_CR5","doi-asserted-by":"crossref","first-page":"205","DOI":"10.25270\/jic\/18.00340","volume":"31","author":"JA Mustapha","year":"2019","unstructured":"Mustapha JA, Brodmann M, Geraghty PJ, Saab F, Settlage RA, Jaff MR. Lutonix BTK Study Investigators Drug-coated vs uncoated percutaneous transluminal angioplasty in infrapopliteal arteries: six-month results of the Lutonix BTK Trial. J Invasive Cardiol. 2019;31:205\u201311.","journal-title":"J Invasive Cardiol"},{"issue":"17","key":"4202_CR6","doi-asserted-by":"publisher","first-page":"e1445","DOI":"10.4244\/EIJ-D-21-00444","volume":"17","author":"F Liistro","year":"2022","unstructured":"Liistro F, Weinberg I, Almonacid Popma A, Shishehbor MH, Deckers S, Micari A. Paclitaxel-coated balloons versus percutaneous transluminal angioplasty for infrapopliteal chronic total occlusions: the IN.PACT BTK randomised trial. EuroIntervention. 2022;17(17):e1445\u201354. https:\/\/doi.org\/10.4244\/EIJ-D-21-00444.","journal-title":"EuroIntervention"},{"key":"4202_CR7","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1016\/j.jcin.2015.07.011","volume":"8","author":"T Zeller","year":"2015","unstructured":"Zeller T, Beschorner U, Pilger E, et al. Paclitaxel-coated balloon in infrapopliteal arteries: 12-month results from the BIOLUX P-II randomized trial (BIOTRONIK\u2019s first in man study of the Passeo-18 LUX drug releasing PTA balloon catheter vs. the uncoated Passeo-18 PTA balloon catheter in subjects requiring revascularization of infrapopliteal arteries). JACC Cardiovasc Interv. 2015;8:1614\u201322. https:\/\/doi.org\/10.1016\/j.jcin.2015.07.011.","journal-title":"JACC Cardiovasc Interv"},{"issue":"22","key":"4202_CR8","doi-asserted-by":"publisher","first-page":"2290","DOI":"10.1016\/j.jacc.2012.08.989","volume":"60","author":"D Scheinert","year":"2012","unstructured":"Scheinert D, Katsanos K, Zeller T, et al. A prospective randomized multicenter com- parison of balloon angioplasty and infrapopliteal stenting with the sirolimus-eluting stent in patients with ischemic peripheral arterial disease: 1-year results from the ACHILLES trial. J Am Coll Cardiol. 2012;60(22):2290\u20135. https:\/\/doi.org\/10.1016\/j.jacc.2012.08.989.","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"4202_CR9","doi-asserted-by":"publisher","first-page":"587e91","DOI":"10.1016\/j.jacc.2012.04.035","volume":"60","author":"A Rastan","year":"2012","unstructured":"Rastan A, Brechtel K, Krankenberg H, et al. Sirolimus-eluting stents for treatment of infrapopliteal arteries reduce clinical event rate compared to bare- metal stents: long-term results from a randomized trial. J Am Coll Cardiol. 2012;60(7):587e91. https:\/\/doi.org\/10.1016\/j.jacc.2012.04.035.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"4202_CR10","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.jvs.2011.07.099","volume":"55","author":"M Bosiers","year":"2012","unstructured":"Bosiers M, Scheinert D, Peeters P, et al. Randomized comparison of everolimus-eluting versus bare-metal stents in patients with critical limb ischemia and infrapopliteal arterial occlusive disease. J Vasc Surg. 2012;55(2):390\u20138. https:\/\/doi.org\/10.1016\/j.jvs.2011.07.099.","journal-title":"J Vasc Surg"},{"issue":"1","key":"4202_CR11","doi-asserted-by":"publisher","first-page":"49","DOI":"10.23736\/S0021-9509.16.09546-X","volume":"58","author":"MJ Bosiers","year":"2017","unstructured":"Bosiers MJ, Deloose K, Peeters P, Torsello G, Zeller T, Scheinert D, et al. Outcome of a drug-eluting stent in longer below-the-knee lesions in patients with critical limb ischemia. J Cardiovasc Surg (Torino). 2017;58(1):49\u201354. https:\/\/doi.org\/10.23736\/S0021-9509.16.09546-X.","journal-title":"J Cardiovasc Surg (Torino)"},{"key":"4202_CR12","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1007\/s00270-014-0904-3","volume":"37","author":"F Fanelli","year":"2014","unstructured":"Fanelli F, Cannavale A, Gazzetti M, et al. Calcium burden assessment and impact on drug-eluting balloons in peripheral arterial disease. Cardiovasc Intervent Radiol. 2014;37:898\u2013907. https:\/\/doi.org\/10.1007\/s00270-014-0904-3.","journal-title":"Cardiovasc Intervent Radiol"},{"key":"4202_CR13","doi-asserted-by":"publisher","first-page":"3S","DOI":"10.1016\/j.jvs.2019.02.016","volume":"69","author":"MS Conte","year":"2019","unstructured":"Conte MS, Bradbury AW, Kolh P, White JV, Dick F, Fitridge R, et al. GVG Writing Group. Global vascular guidelines on the management of chronic limb-threatening ischemia. J Vasc Surg. 2019;69:3S-125S. https:\/\/doi.org\/10.1016\/j.jvs.2019.02.016.","journal-title":"J Vasc Surg"},{"issue":"4","key":"4202_CR14","doi-asserted-by":"publisher","first-page":"133","DOI":"10.31083\/j.rcm2504133","volume":"25","author":"HJ Cui","year":"2024","unstructured":"Cui HJ, Wu YF. Bioresorbable scaffolds for below-the-knee arterial disease: a literature review of new developments. Rev Cardiovasc Med. 2024;25(4):133. https:\/\/doi.org\/10.31083\/j.rcm2504133.","journal-title":"Rev Cardiovasc Med"},{"key":"4202_CR15","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1161\/CIRCULATIONAHA.119.043467","volume":"140","author":"M Sabate","year":"2019","unstructured":"Sabate M, Alfonso F, Cequier A, Romani S, Bordes P, Serra A, et al. Magnesium-based resorbable scafold versus permanent metallic sirolimus-eluting stent in patients with ST-segment elevation myocardial infarction: the MAGSTEMI randomized clinical trial. Circulation. 2019;140:1904\u201316. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.119.043467.","journal-title":"Circulation"},{"key":"4202_CR16","doi-asserted-by":"publisher","first-page":"e167","DOI":"10.4244\/EIJ-D-22-00718","volume":"19","author":"M Seguchi","year":"2023","unstructured":"Seguchi M, Baumann-Zumstein P, Fubel A, Waksman R, Haude M, Galli S, et al. Preclinical evaluation of the degradation kinetics of third-generation resorbable magnesium scafolds. EuroIntervention. 2023;19:e167\u201375. https:\/\/doi.org\/10.4244\/EIJ-D-22-00718.","journal-title":"EuroIntervention"},{"issue":"2","key":"4202_CR17","first-page":"66","volume":"2","author":"GA Leibundgut","year":"2018","unstructured":"Leibundgut GA. Novel Radiopaque, Bioresorbable Tyrosine-Derived Polymer for Cardiovascular Scaffolds. Insert to Cardiac Interventions Today Europe. 2018;2(2):66\u201370.","journal-title":"Insert to Cardiac Interventions Today Europe."},{"issue":"6","key":"4202_CR18","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1177\/1526602818799736","volume":"25","author":"RL Varcoe","year":"2018","unstructured":"Varcoe RL, Thomas SD, Lennox AF. Three-year results of the Absorb everolimus-eluting bioresorbable vascular scaffold in infrapopliteal arteries. J Endovasc Ther. 2018;25(6):694\u2013701. https:\/\/doi.org\/10.1177\/1526602818799736.","journal-title":"J Endovasc Ther"},{"issue":"1","key":"4202_CR19","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2305637","volume":"390","author":"RL Varcoe","year":"2024","unstructured":"Varcoe RL, DeRubertis BG, Kolluri R, Krishnan P, Metzger DC, Bonaca MP, et al. Drug-eluting resorbable scaffold versus angioplasty for infrapopliteal artery disease. N Engl J Med. 2024;390(1):9\u201319. https:\/\/doi.org\/10.1056\/NEJMoa2305637.","journal-title":"N Engl J Med"}],"container-title":["CardioVascular and Interventional Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00270-025-04202-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00270-025-04202-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00270-025-04202-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T01:09:33Z","timestamp":1761786573000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00270-025-04202-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,22]]},"references-count":19,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["4202"],"URL":"https:\/\/doi.org\/10.1007\/s00270-025-04202-8","relation":{},"ISSN":["1432-086X"],"issn-type":[{"value":"1432-086X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,22]]},"assertion":[{"value":"1 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Consent for publication was obtained for every individual person\u2019s data included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}}]}}